Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06365853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06365853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 29, 2024
Completion date
February 28, 2027
Enrollment
108 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

folate receptor-alpha positive, recurrent ovarian cancer